CTRI/2024/02/063075已完成3 期
A prospective, multi-arm, open label, single center clinical study to evaluate the safety and efficacy of Aller GI health supplements in controlling sinusitis, rhinitis and skin allergy - NI
IFE AVEDA0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients of age between 18 to 65 years.
- •2.Patients having symptoms of allergic rhinitis, sinusitis and skin allergy.
- •3.Scores from the global scale atopic dermatitis vIGA
- •4.Patients willing to comply by the study procedures and sign an informed consent form.
排除标准
- •1.Patients with poorly controlled Hypertension or with uncontrolled Diabetes Mellitus and having a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
研究者
相似试验
招募中
4 期
Zolsoma Tablet in Sleep DisorderCTRI/2021/10/037106Pulse Pharmaceuticals Pvt Ltd
进行中（未招募）
1 期
FUlvestrant in gynecological Cancers that are potentially Hormone Sensitive: the FUCHSia studyendometrial stromal sarcoma uterine adenosarcoma endometrial carcinoma sex cord stromal tumors serous ovarian cancerEUCTR2017-005018-76-NLniversity Hospitals Leuven200
招募中
2 期
An open-label, single arm, prospective, multi-center, tandem two stage designed, phase II study to evaluate the efficacy of Fulvestrant in women with recurrent/metastatic estrogen receptor positive gynecological malignanciesNL-OMON50189Z Leuven80
进行中（未招募）
1 期
FUlvestrant in gynecological Cancers that are potentially Hormone Sensitive: the FUCHSia studyendometrial stromal sarcomauterine adenosarcomaendometrial carcinomasex cord stromal tumorsserous ovarian cancerEUCTR2017-005018-76-BEniversity Hospitals Leuven200
进行中（未招募）
1 期
Evaluate Efficacy and Safety in Chinese Patients with Infantile-Onset Pompe Disease with One Year Alglucosidase Alfa TreatmentEUCTR2021-004047-25-Outside-EU/EEASanofi(China) Investment Co Ltd, Shanghai Branch